Galectin Therapeutics (GALT) Current Leases (2020 - 2026)
Galectin Therapeutics (GALT) posted quarterly Current Leases of $6000.0 for Q1 2026, down 91.18% year-over-year from $68000.0 in Q1 2025, and down 72.73% quarter-over-quarter from $22000.0 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Current Leases (2020 - 2026) Analysis & Trends
Galectin Therapeutics' Current Leases history runs 7 years deep, the most recent figure standing at $6000.0 for Q1 2026.
- In Q1 2026, Current Leases fell 91.18% year-over-year to $6000.0; the TTM figure through Mar 2026 stood at $6000.0 (down 91.18% YoY), while the FY2025 annual figure was $22000.0, up 15.79% from the prior year.
- Current Leases for Q1 2026 stood at $6000.0, down from $22000.0 in the prior quarter.
- The five-year high for Current Leases was $68000.0 in Q1 2025, with the low at $6000.0 in Q1 2026.
- The 5-year median for Current Leases is $40000.0 (2022), against an average of $36764.7.
- The sharpest annual moves came in 2022 and 2026: Current Leases surged 400.0% in 2022, then tumbled 91.18% in 2026.
- Galectin Therapeutics' Current Leases stood at $40000.0 in 2022, then grew by 15.0% to $46000.0 in 2023, then sank by 58.7% to $19000.0 in 2024, then gained by 15.79% to $22000.0 in 2025, then slumped by 72.73% to $6000.0 in 2026.
- Business Quant data shows GALT's Current Leases at $6000.0 in Q1 2026, $22000.0 in Q4 2025, and $37000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | 59,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | 37,000.00 |
| Jun 30, 2025 | 52,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 19,000.00 |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 48,000.00 |
| Dec 31, 2023 | 46,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Jun 30, 2023 | 43,000.00 |
| Mar 31, 2023 | 42,000.00 |
| Dec 31, 2022 | 40,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 28,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | 19,000.00 |